{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:17:27Z","timestamp":1767968247964,"version":"3.49.0"},"reference-count":4,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1111\/bjh.70222","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T09:03:30Z","timestamp":1761123810000},"page":"2659-2660","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Aligning patient\u2010reported priorities in immune thrombocytopenia with clinical and regulatory advances: Insights from rilzabrutinib"],"prefix":"10.1111","volume":"207","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7740-1563","authenticated-orcid":false,"given":"Muhammad Ammar","family":"Hasan","sequence":"first","affiliation":[{"name":"Letterkenny University Hospital  Letterkenny Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1169-4507","authenticated-orcid":false,"given":"Mobeen","family":"Abid","sequence":"additional","affiliation":[{"name":"Karachi Medical and Dental College  Karachi Sindh Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5694-6003","authenticated-orcid":false,"given":"Hamza Maqsood","family":"Khan","sequence":"additional","affiliation":[{"name":"Karachi Medical and Dental College  Karachi Sindh Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"e_1_2_2_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20257"},{"key":"e_1_2_2_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025012345"},{"key":"e_1_2_2_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27539"},{"key":"e_1_2_2_5_1","unstructured":"U.S. Food and Drug Administration.FDA approves Wayrilz (rilzabrutinib) for immune thrombocytopenia. FDA;2025. Available from:https:\/\/www.fda.gov\/drugs\/news\u2010events\u2010human\u2010drugs\/fda\u2010approves\u2010drug\u2010treat\u2010adults\u2010persistent\u2010or\u2010chronic\u2010immune\u2010thrombocytopenia"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.70222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T11:44:43Z","timestamp":1767959083000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.70222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":4,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/bjh.70222"],"URL":"https:\/\/doi.org\/10.1111\/bjh.70222","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"2025-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}